Livanova Plc (LIVN) valuation
Livanova Plc P/E ratio history
Livanova Plc trades at 23.3 times its earnings over the last twelve months and 17.5 times the earnings analysts expect over the next twelve.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $61.53 | -$4.45 | n/m | 15.1 |
| Dec 31, 2024 | $46.31 | $1.16 | 39.9 | 13.0 |
| Dec 31, 2023 | $51.74 | $0.32 | 161.7 | — |
| Dec 31, 2022 | $55.54 | -$1.61 | n/m | — |
| Dec 31, 2021 | $87.43 | -$2.72 | n/m | — |
| Dec 31, 2020 | $66.21 | -$7.17 | n/m | — |
| Dec 31, 2019 | $75.43 | -$3.21 | n/m | — |
| Dec 31, 2018 | $91.47 | -$3.91 | n/m | — |
| Dec 31, 2017 | $79.92 | -$0.54 | n/m | — |
| Dec 31, 2016 | $44.97 | -$1.28 | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Livanova Plc valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Livanova PlcLIVN | $4.34B | 23.3 | 17.5 | 3.0 |
| Integer HoldingsITGR | $4.30B | 42.2 | 18.9 | 2.4 |
| Adaptive BiotechnologiesADPT | $4.26B | — | — | 13.8 |
| ErascaERAS | $4.46B | — | — | — |
| Edgewise TherapeuticsEWTX | $4.18B | — | — | — |
| Dianthus TherapeuticsDNTH | $4.50B | — | — | — |
| Indivior PharmaceuticalsINDV | $4.17B | 9.9 | 7.9 | 3.0 |
| CorvelCRVL | $4.17B | 36.5 | — | 4.2 |
| CaredxCDNA | $4.52B | 36.6 | 69.0 | 9.1 |
| Peer median | 36.6 | 18.9 | 4.2 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: LIVN financials · LIVN returns
No forecast, no recommendation. This page describes Livanova Plc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.